Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719665 · ClinicalTrials.gov registry record · NA
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02719665 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT02719665, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects of fish oil supplement (containing parts of omega-3 fatty acids) on inflammation. The investigators are aiming to identify which dose of the fish oil supplement is the most effective. The name of the fish oil supplement is "SPM Emulsion."
Interventions
- DIETARY_SUPPLEMENT SPM Emulsion, Dose-modality
- DIETARY_SUPPLEMENT SPM Softgel, Dose-Modality
- DIETARY_SUPPLEMENT Placebo Softgel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02719665
The ClinicalTrials.gov registry entry for NCT02719665 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SPM Emulsion, Dose-modality is the first listed.
NCT02719665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02719665 about?
NCT02719665 is a clinical study titled "THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease". The purpose of this study is to understand the effects of fish oil supplement (containing parts of omega-3 fatty acids) on inflammation. The investigators are aiming to identify which dose of the fish oil supplement is the most effective. The name of the fish oil supplement is "SPM Emulsion."
What is the current status of trial NCT02719665?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-03. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT02719665?
The interventions under investigation include: SPM Emulsion, Dose-modality (DIETARY_SUPPLEMENT), SPM Softgel, Dose-Modality (DIETARY_SUPPLEMENT), Placebo Softgel (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02719665?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.